AU2251488A - Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system - Google Patents

Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system

Info

Publication number
AU2251488A
AU2251488A AU22514/88A AU2251488A AU2251488A AU 2251488 A AU2251488 A AU 2251488A AU 22514/88 A AU22514/88 A AU 22514/88A AU 2251488 A AU2251488 A AU 2251488A AU 2251488 A AU2251488 A AU 2251488A
Authority
AU
Australia
Prior art keywords
acnpv
baculovirus
csf
production
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22514/88A
Inventor
Robin Clark
James Joseph Devlin
Ernest Seigo Kawasaki
George Martin
Edward O'rourke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of AU2251488A publication Critical patent/AU2251488A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU22514/88A 1987-07-24 1988-07-20 Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system Abandoned AU2251488A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7718887A 1987-07-24 1987-07-24
US077188 1987-07-24

Publications (1)

Publication Number Publication Date
AU2251488A true AU2251488A (en) 1989-03-01

Family

ID=22136589

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22514/88A Abandoned AU2251488A (en) 1987-07-24 1988-07-20 Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system

Country Status (3)

Country Link
AU (1) AU2251488A (en)
CA (1) CA1317244C (en)
WO (1) WO1989001038A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04228066A (en) * 1990-10-23 1992-08-18 Rikagaku Kenkyusho Culture cell for expressing exogenote
US6342216B1 (en) * 1999-03-17 2002-01-29 The Board Of Regents, The University Of Texas System Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
WO2001092484A2 (en) 2000-05-31 2001-12-06 Board Of Regents, The University Of Texas System Adjuvant preparation for the induction of specific immunity
WO2005074524A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
SG158186A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0519170A8 (en) 2004-12-22 2018-05-08 Ambrx Inc human growth hormone formulations comprising an unnaturally encoded amino acid
CA2590462C (en) 2004-12-22 2017-02-28 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
EP2284191A3 (en) 2004-12-22 2011-07-20 Ambrx, Inc. Process for the preparation of hGH
CN101247821B (en) 2005-06-03 2013-01-23 Ambrx公司 Improved human interferon molecules and their uses
KR20080079643A (en) 2005-11-16 2008-09-01 암브룩스, 인코포레이티드 Methods and compositions comprising non-natural amino acids
CA2662753C (en) 2006-09-08 2016-02-23 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
WO2008030614A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
MX2009002523A (en) 2006-09-08 2009-03-20 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their uses.
ATE554785T1 (en) 2007-03-30 2012-05-15 Ambrx Inc MODIFIED FGF-21 POLYPEPTIDES AND THEIR USE
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
KR101656107B1 (en) 2007-11-20 2016-09-08 암브룩스, 인코포레이티드 Modified insulin polypeptides and their uses
MX344166B (en) 2008-02-08 2016-12-07 Ambrx Inc Modified leptin polypeptides and their uses.
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
EP3216800A1 (en) 2008-09-26 2017-09-13 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
NZ607477A (en) 2008-09-26 2014-09-26 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
CN107674121A (en) 2009-12-21 2018-02-09 Ambrx 公司 Bovine somatotropin polypeptide and its purposes by modification
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
WO2012024452A2 (en) 2010-08-17 2012-02-23 Ambrx, Inc. Modified relaxin polypeptides and their uses
AR083006A1 (en) 2010-09-23 2013-01-23 Lilly Co Eli FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
SI3412302T1 (en) 2014-10-24 2021-09-30 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
AU2018219283B2 (en) 2017-02-08 2022-05-19 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127839B1 (en) * 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
NZ228031A (en) * 1984-07-06 1991-12-23 Sandoz Ltd Primate gm-csf and method of extraction
HU215241B (en) * 1986-10-24 1998-11-30 Cetus Corp. Process for producing new forms of colony stimulating factor-1 and expression cassette, vector and recombinant host cells used in the process

Also Published As

Publication number Publication date
WO1989001038A1 (en) 1989-02-09
CA1317244C (en) 1993-05-04

Similar Documents

Publication Publication Date Title
AU2251488A (en) Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system
AU4016289A (en) A novel human physiologically active polypeptide
AU648982B2 (en) Capsule production using biologically active substrates
AU6906087A (en) Perimeter resin feeding of composite structures
AU7469787A (en) Process for the genetic modification of yeast
AU3167389A (en) Production of 2',3'-dideoxy-2',3'-didehydronucleosides
AU588981B2 (en) Improvements relating to the production of beer
AU5300386A (en) Pharmaceutically active podophyllotoxins
AU1032992A (en) Pharmacologically active substituted oxybenzamides
EP0202094A3 (en) Process for producing physiologically active substance
AU582956B2 (en) Production of ceramic materials
AU5061985A (en) System of modular construction for a covered structure
HUT50758A (en) Process for production of optically active naftotiasepinons
AU596678B2 (en) Production of crystalline tribromostyrene
AU1050488A (en) Active control of vibration
AU1969688A (en) Manufacture of solar cells
AU3735389A (en) Production of alcohols
AU558388B2 (en) Production of n-acylphenylalanines
AU1572588A (en) Production of bioadhesive precursor protein analogs by genetically-engineered organisms
AU6581186A (en) Pharmaceutically active hererocyclic compounds
AU618653B2 (en) Production of sugar compounds
EP0212867A3 (en) Antihelmintic avermectin derivatives produced by the fermentation of a microorganism
AU5732186A (en) Production of monotertiarybutyl toluinediamines
EP0207636A3 (en) Process for producing optically active dichloropropanol using microorganism
AU592862B2 (en) Yeast production of streptolinase